Enliven Therapeutics (ELVN) Equity Average (2019 - 2026)

Enliven Therapeutics has disclosed Equity Average across 8 years of filings, most recently posting $456.5 million for Q1 2026.

• Equity Average for Q1 2026 came in at $456.5 million, up 52.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $456.5 million (up 52.63% YoY), and the FY2025 annual result was $384.7 million, up 38.45% from the prior year.
• Equity Average came in at $456.5 million for Q1 2026 at Enliven Therapeutics, down from $467.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $482.3 million in Q3 2025 to a low of -$72.5 million in Q4 2022.
• The 5-year median for Equity Average is $285.2 million (2023), against an average of $233.1 million.
• Across the five-year window, Equity Average slumped 356.56% in 2022 and soared 621.77% in 2023, its largest moves.
• Enliven Therapeutics' Equity Average stood at -$72.5 million in 2022, then soared by 450.29% to $253.8 million in 2023, then gained by 17.85% to $299.1 million in 2024, then surged by 56.41% to $467.9 million in 2025, then dropped by 2.43% to $456.5 million in 2026.
• The last three Equity Average figures came in at $456.5 million (Q1 2026), $467.9 million (Q4 2025), and $482.3 million (Q3 2025), per Business Quant data.